See footnote about the use of pro forma financial information Fourth Quarter 2016 Highlights: Consolidated total revenue increased 9.9% to a record $24.5 million compared to fourth quarter 2015 revenue of $22.3 million Consolidated gross profit increased 17.4% to $17.5 million compared to fourth

BELGRADE, Mont. , March 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2016 ,

BELGRADE, Mont. , Feb. 22, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Carl O’Connell as the permanent CEO, effective February 17th, 2017 . Mr.

BELGRADE, Mont. , Jan. 23, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that on January 21, 2017 , Dan Goldberger resigned as Chief

BELGRADE, Mont. , Jan. 19, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced the issuance of new convertible promissory notes on January

BELGRADE, Mont. , Jan. 18, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced the closing of a registered direct offering conducted without

BELGRADE, Mont. , Jan. 13, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced that it has entered into an agreement with certain holders of

Record Fourth Quarter 2016 Revenue is estimated to be at least $24.5 million which represents 10.0% year on year growth Full Year 2016 Revenue is estimated to be at least $90.0 million which represents 4.1% year on year growth Fourth Quarter 2016 Adjusted EBITDA* is estimated to be at least $1.25

BELGRADE, Mont. , Nov. 23, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration ( FDA ) has cleared the Xsert Lumbar Expandable Interbody

BELGRADE, Mont. , Nov. 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today the closing of its rights offering (the "Offering") of units at a